CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$63.99 USD
+2.89 (4.73%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $63.88 -0.11 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRSP 63.99 +2.89(4.73%)
Will CRSP be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
Other News for CRSP
Is CRSP showing upside potential? Crossed Above 50 Day Moving Average shows up after climbing 4.73%
CRISPR Therapeutics (CRSP) Gains as FDA Eases Approval Pathway
Gene editing therapy companies rise on word of streamlined FDA approval process
FDA to Expedite Gene-Editing Approval Process, Impacting CRSP
FDA to speed up gene editing therapy approvals, Bloomberg reports